Natera Inc (NASDAQ:NTRA) shares saw unusually-high trading volume on Wednesday . Approximately 2,903,275 shares were traded during mid-day trading, an increase of 380% from the previous session’s volume of 604,363 shares.The stock last traded at $19.84 and had previously closed at $16.66.
NTRA has been the subject of several research reports. BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a research report on Friday, December 7th. ValuEngine lowered Natera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 9th. Finally, Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research report on Thursday, January 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Natera presently has a consensus rating of “Buy” and an average target price of $27.75.
The stock has a market cap of $1.03 billion, a PE ratio of -9.02 and a beta of 1.84. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.44 and a quick ratio of 2.32.
In related news, insider Matthew Rabinowitz sold 5,672 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $16.00, for a total transaction of $90,752.00. Following the completion of the transaction, the insider now owns 1,288,853 shares in the company, valued at approximately $20,621,648. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Sheena sold 23,356 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $20.51, for a total value of $479,031.56. Following the transaction, the insider now owns 294,758 shares of the company’s stock, valued at approximately $6,045,486.58. The disclosure for this sale can be found here. Insiders have sold a total of 40,194 shares of company stock valued at $742,949 in the last 90 days. Insiders own 13.18% of the company’s stock.
A number of institutional investors have recently made changes to their positions in NTRA. Bank of New York Mellon Corp raised its stake in Natera by 9.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 650,968 shares of the medical research company’s stock valued at $12,251,000 after acquiring an additional 58,224 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Natera during the 3rd quarter valued at $1,915,000. Wells Fargo & Company MN raised its stake in Natera by 6.9% during the 3rd quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock valued at $1,266,000 after acquiring an additional 3,411 shares in the last quarter. SG Americas Securities LLC bought a new stake in Natera during the 3rd quarter valued at $2,897,000. Finally, JPMorgan Chase & Co. raised its stake in Natera by 209.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 160,128 shares of the medical research company’s stock valued at $3,833,000 after acquiring an additional 108,310 shares in the last quarter. 90.05% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Natera (NTRA) Sees Strong Trading Volume” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4224697/natera-ntra-sees-strong-trading-volume.html.
About Natera (NASDAQ:NTRA)
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Understanding Options Trading
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.